INTRODUCTION
• Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system.
1,2
The most recent estimates of MS prevalence are 2.3 million individuals worldwide, and approximately 400,000 people in the United States. 3 The prevalence of MS is much higher among females than among males 2 • Relapsing-remitting multiple sclerosis (RRMS) accounts for approximately 85% of MS diagnoses 4 and is characterized by acute episodes of worsening neurological function with subsequent full or partial recovery
• RRMS is treated with disease-modifying therapies (DMTs) indicated to reduce relapses and/or slow disease progression. Glatiramer acetate (GA) is a widely used DMT administered subcutaneously by self-injection. GA was first approved in the US in 1996 as a daily 20 mg injection, and became available as a 40 mg formulation with a 3-times weekly (TIW) injection schedule in the US in 2014
• 
OBJECTIVE
• The objective of this study was to compare adherence and discontinuation between patients treated with GA 40 mg TIW and those treated with the oral DMTs, using a large US claims database reflecting patients' real-world behavior
METHODS

Study Design and Data Source
• Retrospective study using administrative claims data from a large US health plan with national coverage during the period October 2012 through December 2014
Subject Selection
Commercial health plan members with ≥1 pharmacy claim for a DMT: GA (20 mg/mL daily or 40 mg/mL TIW), interferon beta-1a, interferon beta-1b, ngolimod, teri unomide, or dimethyl fumarate during the identi cation period April 1, 2013 -June 30, 2014; date of the rst DMT claim = index date; DMT lled on the index date = index DMT N=13,102
Age ≥18 years and ≥3 months of continuous health plan enrollment after the index date (post-index period) n=12,276 6 months of continuous health plan enrollment before the index date (pre-index period) n=9,247
MS diagnosis (ICD-9-CM 340) during pre-index period and/or during the rst 3 months of post-index n=8,588
Initiating index DMT on the index date (i.e. no claims for the index DMT during pre-index period) n=2,517
GA 40 mg TIW cohort: patients with GA 40 mg on their index dates or who switched to GA 40 mg during post-index and had ≥90 days of post-index after switch; for switchers, the date of the switch to GA 40 mg became the new index date n=232
Oral DMT cohort: patients whose index DMTs were ngolimod, teri unomide, or dimethyl fumarate and who did not switch to GA 40 mg TIW during post-index n=1,547 
Demographic characteristics
• Age, gender, US census region
Analysis
• All variables were analyzed descriptively, with means and standard deviations for continuous variables and counts and percentages for binary or categorical variables. Differences between the GA 40 mg and oral DMT cohorts were identified with chi-squared statistics and t-tests, adjusting for unequal variance as required
• To account for varying lengths of post-index: -Incidence rate ratios were computed for discontinuation -MPR, PDC, and discontinuation were computed for a uniform period for all patients = the first 180 days of the post-index period -MPR and PDC were compared between patients with maximum post-index periods of 210, 270, and 330 days • Kaplan-Meier curves of time to discontinuation, adjusted for age and gender, were computed across the full post-index period and censored at 330 days of post-index; differences were compared with log-rank statistics 
RESULTS
• The GA 40 mg cohort was older, on average, than the oral DMT cohort (48.5 years versus 45.0 years, P<.001). There was no difference in the gender distribution between the cohorts (Table 1) • The oral DMT cohort had a longer mean post-index period compared with the GA 40 mg cohort, largely based on cohort selection (Table 1 ) • Discontinuation: the GA 40 mg cohort was less likely to have a discontinuation (≥30-day gap in index DMT) compared with the oral DMT cohort for all analyses of discontinuation -The incidence rate ratio of discontinuation was 2.749 (P<.01; Table 2 ) -The rate of discontinuation during the first 180 days of post-index was lower in the GA cohort (P=.001; Table 2 ) -The GA 40 mg cohort was less likely to discontinue during the post-index period (log-rank P<.01; Figures 2 and 3 ). For example, at 90 days, 10% of the glatiramer acetate cohort had discontinued compared with 27% of the oral DMT cohort; at 180 days, 14% of the glatiramer acetate cohort had discontinued compared with 37% of the oral DMT cohort (Figure 2 ) 
Adherence
• The GA 40 mg cohort was more adherent than the oral DMT cohort, as measured both by MPR and PDC (Table 3) . For example, the GA 40 mg cohort had a mean PDC of 0.87, i.e. they possessed their index DMT for 87% of the days they were observed for the PDC calculation, versus the mean PDC of 0.70 in the oral DMT cohort. Differences in mean MPR were not significant in the subsets of patients with maximum 270 and 330 days post-index. Otherwise, all differences were significant at P<.05
• The GA 40 mg cohort also had higher odds of adherence based on the logistic regressions (Figure 4 ). In the regression of adherence over the first 180 days of post-index, the GA 40 mg cohort had 2.1 times higher odds of MPR≥0.80 and 2.7 times higher odds of PDC≥0.80 versus the oral DMT cohort. Thus, the GA 40 mg cohort showed better adherence Valid N = subjects in each cohort with ≥180 days post-index (and with ≥2 claims for index DMT for MPR). 
LIMITATIONS
• There are limitations associated with claims data that must be considered when interpreting these data:
-Diagnosis codes on medical claims may be miscoded, although this is unlikely to have affected this sample; this sample had MS diagnoses codes and received DMTs indicated specifically for MS -We cannot observe whether patients used their index DMTs as prescribed • A large majority of the GA 40 mg cohort switched from a previous DMT (principally GA 20 mg), while a smaller proportion of the oral DMT cohort switched from a previous DMT. The assignment of patients to the GA 40 mg cohort was pragmatic given the recent availability of the 40 mg formulation in the US. Future research, when GA 40 mg has more time on the market, should compare more balanced cohorts with respect to new DMT starts versus DMT switches
CONCLUSIONS
• This real-world analysis suggests that patients in the GA 40 mg/mL cohort were more adherent and less likely to discontinue (i.e. more persistent) compared with the oral DMT cohort
• This improved adherence and persistence may be attributable to the safety profile of GA 40 mg and its convenient/less frequent dosing schedule
